TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Charles River Labs ( (CRL) ) has provided an update.
Charles River Laboratories announced its participation in the Evercore 8th Annual Healthcare Conference on December 3, 2025, where it plans to discuss fourth-quarter demand trends. The company has observed improvements in its DSA net book-to-bill ratio since the third fiscal quarter of 2025, despite potential seasonal impacts on proposal and booking activities during the holiday period. The company remains optimistic about the positive momentum and upward trends in its operations.
The most recent analyst rating on (CRL) stock is a Buy with a $200.00 price target. To see the full list of analyst forecasts on Charles River Labs stock, see the CRL Stock Forecast page.
Spark’s Take on CRL Stock
According to Spark, TipRanks’ AI Analyst, CRL is a Neutral.
Charles River Labs exhibits strong revenue growth and cash flow generation, but faces significant profitability challenges. Technical indicators show positive momentum, but valuation metrics are concerning due to negative earnings. The earnings call highlighted strategic initiatives but also revealed ongoing operational challenges.
To see Spark’s full report on CRL stock, click here.
More about Charles River Labs
Charles River Laboratories International, Inc. operates in the healthcare industry, focusing on providing essential services in Discovery and Safety Assessment (DSA). The company is known for its work in booking activities and key performance indicators in this sector.
Average Trading Volume: 1,028,504
Technical Sentiment Signal: Hold
Current Market Cap: $8.67B
Learn more about CRL stock on TipRanks’ Stock Analysis page.